Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Congenital Cardiomyopathy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Speckle Tracking in Pediatric Patients

NCT00489957
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 17 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

NCT06275893
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy 1, Arrhythmogenic Cardiomyopathy, ACM, ARVC, PKP2
Interventions
IC14
Biological
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting Phase 1 Interventional

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

NCT06228924
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions
TN-401
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Not applicable Interventional

Coronary Artery Disease in Patients With Friedreich's Ataxia

NCT04649866
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
plethysmography
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation

NCT03560167
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Dilated
Interventions
AccuCinch® Ventricular Restoration System
Device
Lead sponsor
Ancora Heart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of CIRC Technologies

NCT05654272
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2042
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

NCT02351856
View directory record Official record
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
ARRY-371797, p38 inhibitor, oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting Phase 2 Interventional

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
LX2006, Usual Care
Genetic · Other
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

NCT05445323
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions
Low dose LX2006, Mid Dose LX2006, High Dose LX2006
Genetic
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 20, 2026, 4:43 AM EDT
Active, not recruiting Phase 2 Interventional

Open-Label Study of AG10 in Patients with Cardiomyopathy

NCT03536767
View directory record Official record
Conditions
Amyloid Cardiomyopathy
Interventions
AG10
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

ATR 1072 in Participants With PRKAG2 Syndrome

NCT07738107
View directory record Official record
Conditions
Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Interventions
ATR 1072
Drug
Lead sponsor
Atrium Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting Phase 1 Interventional

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

NCT07172971
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Results available

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

NCT04572893
View directory record Official record
Conditions
Primary Familial Dilated Cardiomyopathy
Interventions
danicamtiv
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 20, 2026, 4:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

NCT03439514
View directory record Official record
Conditions
Dilated Cardiomyopathy, Lamin A/C Gene Mutation
Interventions
ARRY-371797 (PF-07265803), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting No phase listed Observational

Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

NCT07674758
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Cardiomyopathy, Becker Muscular Dystrophy, Carrier of Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Sacramento, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

NCT03447990
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
Interventions
MYK-491, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 20, 2026, 4:43 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

NCT02316314
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), Cardiac-related blood studies
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Not applicable Interventional

Optimizing Left Ventricular Lead To Improve Cardiac Output

NCT01399801
View directory record Official record
Conditions
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
Interventions
Doppler flow measurement, standard implantation of the LV lead
Procedure
Lead sponsor
Ann Marie Chikowski
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 20, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

NCT02964377
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
(+)- Epicatechin
Drug
Lead sponsor
Craig McDonald, MD
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 20, 2026, 4:43 AM EDT
Completed No phase listed Observational

Heart and Skeletal Muscle Problems in Neuroacanthocytosis

NCT00007228
View directory record Official record
Conditions
Choreatic Disorder
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 4:43 AM EDT
Active, not recruiting No phase listed Observational

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092
View directory record Official record
Conditions
Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 20, 2026, 4:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

NCT06109181
View directory record Official record
Conditions
Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Interventions
LX2020
Genetic
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 20, 2026, 4:43 AM EDT